Abstracts Archive - Page 917 of 2425 - ACR Meeting Abstracts

Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Toshihisa Kojima¹, Masayo Kojima ², Hajime Ishikawa ³, Sakae Tanaka ⁴, Nobuhiko Haga ⁵, Keiichiro Nishida ⁶, Masao Yukioka ⁷, Jun Hashimoto ⁸, Hisaaki Miyahara ⁹, Yasuo Niki ¹⁰, Tomoatsu Kimura ¹¹, Hiromi Oda ¹², Shuji Asai ¹, Koji Funahashi ¹³ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya City University Graduate School of Medicne, Nagoya, Japan, ³Niigata Rheumatic Center, Niigata, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵The University of Tokyo Hospital, Tokyo, Japan, ⁶Okayama University, Graduate School of Medicine, Okayama, Japan, ⁷Yukioka Hospital, Osaka, Japan, ⁸National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ⁹National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, ¹⁰Keio University, School of Medicine, Tokyo, Japan, ¹¹University of Toyama, Faculty of Medicine, Toyama, Japan, ¹²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ¹³Kariya-Toyota General Hosptal, Kariya, Japan
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…
Abstract Number: 2382 • 2019 ACR/ARP Annual Meeting
Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
Paul Emery¹, Ferdinand Breedveld ², Ronald Pedersen ³, Eduardo Jose Campos ⁴, Annette Szumski ⁵ and Tomohiro Hirose ⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Leids Universitair Medisch Centrum, Leiden, Netherlands, ³Pfizer, Collegeville, ⁴Pfizer Japan Inc, Toyko, Japan, ⁵Syneos Health, Princeton, NJ
Background/Purpose: For patients with rheumatoid arthritis (RA) who are treated with etanercept (ETN) plus methotrexate (MTX), dosing down of ETN or withdrawal of MTX are…
Abstract Number: 2383 • 2019 ACR/ARP Annual Meeting
Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
Yuji Yoshioka¹, Shouhei Nagaoka ² and Hiroyuki Hagiyama ³, ¹Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan, ²Yokohama Minami Kyousai Hospital, Yokohama, Kanagawa, Japan, ³Yokohama City Minato Red Cross Hospital, Yokohama
Background/Purpose: Methotrexate-associated lymphoproliferative disorder (MTX-LPD) is important complication in the rheumatoid arthritis (RA) treatment. There were few reports about clinical features of MTX-LPD and RA…
Abstract Number: 2384 • 2019 ACR/ARP Annual Meeting
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
Silva Pukšić¹, Joško Mitrović ², Melanie-Ivana Čulo ², Marcela Živković ³, Biserka Orehovec ⁴, Dubravka Bobek ⁵, Marko Lucijanić ⁶ and Jadranka Morović-Vergles ⁷, ¹Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ²Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, ³Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁴Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, ⁵Department of Physical Medicine and Rehabilitation with Rheumatology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁶Department of Hematology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁷Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, School of Medicine,Zagreb, Croatia, Zagreb, Croatia
Background/Purpose: Rheumatoid arthritis (RA) patients perceive reduced health-related quality of life (HRQOL) through functional disability, pain, increased fatigue and impaired psychological functioning. Previous trials demonstrated…
Abstract Number: 2385 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Runyue Huang¹, Qingchun Huang ², Jiaqi Wu ³, Xiao Cai ⁴, Xiumin Chen ⁴, Yue Zhao ⁴, Yongliang Chu ², Jianyong Zhang ⁵, Jianhong Peng ⁶, Zhisheng Huang ⁷, Xianghong Chen ², Zehao Liu ⁸ and Aihua Ou ², ¹The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China;, Guangzou, Guangdong, China (People's Republic), ²The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ³Section Rheumatology Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzou, China (People's Republic), ⁴The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzou, China (People's Republic), ⁵Shenzhen Hospital of Traditional Chinese Medicine, Shenzhen, China (People's Republic), ⁶Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China (People's Republic), ⁷Guangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Huandu, China (People's Republic), ⁸Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic)
Background/Purpose: In recent years, the combination therapies of conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) with Chinses medicine has prevailed for the treatment of rheumatoid arthritis…
Abstract Number: 2386 • 2019 ACR/ARP Annual Meeting
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Jesus Tornero¹, Mercedes Alperi-López ², Ivan Castellvi ³, Juan José de Agustín de Oro ⁴, Alejandro Escudero ⁵, Rosario Garcia-Vicuña ⁶, Miguel Angel González-Gay ⁷, Cristina Hidalgo ⁸, Esteban Rubio ⁹, Raimon Sanmarti ¹⁰, Núria Casamira ¹¹ and Jaime Calvo-Alen ¹², ¹Hospital de Guadalajara, Guadalajara, Spain, ²Hospital Universitario Central de Asturias, Oviedo, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁶Hospital Universitario de La Princesa, Madrid, Spain, ⁷Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Medical Department, Gebro Pharma S.A., Barcelona, Spain, ¹²Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease…
Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
isabel Hernandez Rodriguez¹, Zulema Rosales Rosado ¹, pia Lois ¹, Cristina Lajas ¹, Judit Font Urgelles ², Juan Angel Jover Jover ¹ and lydia Abasolo Alcazar ¹, ¹HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…
Abstract Number: 2388 • 2019 ACR/ARP Annual Meeting
Patient Characteristics Associated with Long Term Glucocorticoid Use in a Commercially Insured Incident RA Cohort
Beth Wallace¹, Yuqing Gao ², Paul Lin ³, Neil Kamdar ⁴, Jeffrey Curtis ⁵, Kenneth Saag ⁵, Daniel Clauw ⁶ and Akbar Waljee ⁷, ¹Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Institute for Healthcare Policy and Innovation, University of Michigan Medical School, Ann Arbor, MI, ⁴Departments of Obstetrics & Gynecology, Emergency Medicine, Surgery, and Physical Medicine and Rehabilitation, Michigan Medicine, Ann Arbor, MI, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁷Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Gastroenterology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI
Background/Purpose: Prior descriptive work revealed high rates of long term (≥3 months) glucocorticoid (GC) utilization in a commercially insured incident RA cohort [1]. We aim…
Abstract Number: 2389 • 2019 ACR/ARP Annual Meeting
Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
L Douglas Graham ¹ and Lee Graham¹, ¹Du Page Medical Group, Westmont, IL
Background/Purpose: Rheumatologists have been encouraged to achieve low disease activity state when treating rheumatoid arthritis (RA). If it cannot be achieved with initial therapy, experts…
Abstract Number: 2390 • 2019 ACR/ARP Annual Meeting
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Melanie Hagen¹, Koray Tascilar ², Michaela Reiser ³, Judith Haschka ⁴, Arnd Kleyer ⁵, Larissa Valor ⁶, Bernhard Manger ⁷, Georg Schett ⁸ and Jürgen Rech ⁹, ¹Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ⁷Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁸Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Achieving remission is the ultimate treatment goal in patients with rheumatoid arthritis (RA). With the development and wider use of highly effective disease modifying…
Abstract Number: 2391 • 2019 ACR/ARP Annual Meeting
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Ana Goico ¹, Anoka Martis¹, Chistopher Kabir ¹, David Mael ¹ and Shoeb Mohammed ¹, ¹Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Tumor necrosis factor (TNF), a pathogenic inflammatory mediator in Rheumatoid Arthritis (RA), has been shown to play an essential role in the pathophysiology of insulin resistance.…
Abstract Number: 2392 • 2019 ACR/ARP Annual Meeting
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis
Takayasu Ando¹, Takeshi Suzuki ², Yutaka Gotou ¹ and Kimito Kawahata ³, ¹Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology and Allergology, St. Marianna University School of Medicine, Tokyo, Japan
Background/Purpose: In daily practice, our rheumatologist has experienced different clinical feature of elderly-onset rheumatoid arthritis (EORA) compared with younger-onset RA (YORA). In EORA patients, serological…
Abstract Number: 2393 • 2019 ACR/ARP Annual Meeting
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz ², Maryam Sadiq ³, Muhammad Salick ⁴, Yahya Nomaan ⁵, Nusrum Iqbal ⁶, Sandipan Bhattacharjee ⁷, Lary Prokop ⁸ and C. Kent Kwoh ⁷, ¹University of Arizona College of Medicine, Tucson, AZ, ²Mayo Hospital Rochester, Rochester, MN, ³Nishtar Medical College, University of Health Sciences, Lahore, Albany, NY, ⁴Albany Medical Center, Albany, NY, ⁵Phoenix Children's Hospital, Phoenix, AZ, ⁶St Joseph's Hospital, Tucson AZ, Tucson, AZ, ⁷University of Arizona, Tucson, AZ, ⁸Mayo Clinic, Rochestor, MN
Background/Purpose: Importance The efficacy of Janus kinase (JAK) inhibitors is well established across a range of diseases. However, there is a major concern regarding the potential risk of an increased…
Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].